Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 21, 2006

Lilly’s Glioblastoma Study Closed

  • Eli Lilly's  has stopped its study evaluating enzastaurin in recurrent glioblastoma, under the recommendation of the External Data Monitoring Committee (DMC). The Phase III study was evaluating enzastaurin for the treatment of an aggressive and recurrent form of brain cancer.

    Results of this planned interim analysis suggested that enzastaurin would not meet the primary endpoint of improvement in progression-free survival over an existing chemotherapy. Lilly has thus contacted all study investigators to inform them of the decision.

    "Given the independently validated response rate of 22% in a Phase II trial, we plan to thoroughly review the data from this interim analysis and apply the insights learned to the glioblastoma program,” says Richard Gaynor, M.D., vp, cancer research and global oncology platform leader for Eli Lilly. “Based on preclinical and clinical evidence, the company also remains fully committed to the continued development of enzastaurin."



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »